Pure Biologics Spólka Akcyjna Total Liabilities

Latest as of September 2025: zł20.72 Million PLN ≈ $5.70 Million USD

Pure Biologics Spólka Akcyjna total liabilities. Based on the latest financial reports, Pure Biologics Spólka Akcyjna (PUR) has total liabilities worth zł20.72 Million PLN (≈ $5.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Pure Biologics Spólka Akcyjna to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Pure Biologics Spólka Akcyjna (2016–2024)

Total liabilities of Pure Biologics Spólka Akcyjna from 2016 to 2024. This chart illustrates how Pure Biologics Spólka Akcyjna's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Pure Biologics Spólka Akcyjna to see how much of total assets are deployed in long-term investments.

Pure Biologics Spólka Akcyjna Competitors by Total Liabilities

The table below lists competitors of Pure Biologics Spólka Akcyjna ranked by their total liabilities.

Company	Country	Total Liabilities
Mears Group plc LSE:MER	UK	GBX546.62 Million
Hexicon AB ST:HEXI	Sweden	Skr1.03 Billion
Fidelity Asian Values LSE:FAS	UK	GBX6.54 Million
IDOX plc LSE:IDOX	UK	GBX71.48 Million
Tesoro Minerals Corp. V:TES	Canada	CA$40.62K
Terregra Asia Energy PT JK:TGRA	Indonesia	Rp196.83 Billion
Picton Property Income Ltd LSE:PCTN	UK	GBX229.67 Million
Skin Elements Ltd AU:SKN	Australia	AU$429.34K

Liability Composition Analysis (2016–2024)

This chart breaks down Pure Biologics Spólka Akcyjna's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PUR asset base.

Liquidity & Leverage Metrics

Pure Biologics Spólka Akcyjna Total Liabilities Ratios Explained

Pure Biologics Spólka Akcyjna total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	0.06	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.07	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	15.58	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pure Biologics Spólka Akcyjna's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pure Biologics Spólka Akcyjna (2016–2024)

The table below shows the annual total liabilities of Pure Biologics Spólka Akcyjna from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	zł15.46 Million ≈ $4.25 Million	-25.84%
2023-12-31	zł20.84 Million ≈ $5.74 Million	+41.69%
2022-12-31	zł14.71 Million ≈ $4.05 Million	+90.97%
2021-12-31	zł7.70 Million ≈ $2.12 Million	-64.71%
2020-12-31	zł21.83 Million ≈ $6.01 Million	+49.80%
2019-12-31	zł14.57 Million ≈ $4.01 Million	+234.41%
2018-12-31	zł4.36 Million ≈ $1.20 Million	+290.25%
2017-12-31	zł1.12 Million ≈ $307.30K	+74.43%
2016-12-31	zł640.12K ≈ $176.17K	--

About Pure Biologics Spólka Akcyjna

WAR:PUR Poland Biotechnology

Market Cap

$4.35 Million

zł15.82 Million PLN

Market Cap Rank

#28763 Global

#329 in Poland

Share Price

zł1.40

Change (1 day)

+0.58%

52-Week Range

zł1.38 - zł5.37

All Time High

zł142.00